Wedbush Initiates Coverage On Monte Rosa Therapeutics with Outperform Rating, Announces Price Target of $11
Portfolio Pulse from Benzinga Newsdesk
Wedbush analyst Robert Driscoll has initiated coverage on Monte Rosa Therapeutics (NASDAQ:GLUE) with an Outperform rating and set a price target of $11. This initiation could signal confidence in Monte Rosa Therapeutics' future performance and potential growth.
February 15, 2024 | 1:46 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Wedbush analyst Robert Driscoll initiated coverage on Monte Rosa Therapeutics with an Outperform rating and a price target of $11, indicating a positive outlook on the company's stock.
The initiation of coverage by a reputable analyst with an Outperform rating and a specific price target usually signals a positive outlook on the stock's future performance. This can often lead to increased investor interest and potentially a rise in stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100